Movement Alert|Astera Labs, Inc. Rises 6.76% in Regular Trading, Morgan Stanley Raises Target Price to $335 Amid Sector Rebound

Market Focus
Aug 04

On August 4, Astera Labs, Inc. rose 6.76% in regular trading, reaching approximately $350.09 per share, with turnover of $294 million. The rally was driven by multiple catalysts including a major target price upgrade from Morgan Stanley and broad semiconductor sector strength.

Morgan Stanley raised its target price on the company from $240 to $335, maintaining an Overweight rating, citing the company's strong positioning in AI infrastructure growth. Previously, Barclays had also raised its target price from $200 to $325, reflecting institutional consensus on the high-speed connectivity chip segment. The average analyst target now stands at $321.63 according to FactSet polling.

Additionally, the company is scheduled to report second-quarter earnings after market close on the same day, with market expectations for EPS at $0.42, prompting pre-earnings positioning by investors. The move also represents a sharp reversal from the prior session's 5.85% decline, which was attributed to sector-wide selling pressure, suggesting an oversold bounce amplified by the bullish catalysts.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10